BRCA Reversion Mutations Detected in Ovarian Tumor cfDNA

Acquired reversion mutations in BRCA1/2 are detectable in circulating cell-free DNA in women with high-grade serous ovarian cancer.
Acquired reversion mutations in BRCA1/2 are detectable in circulating cell-free DNA in women with high-grade serous ovarian cancer.

Acquired reversion mutations in BRCA1/2 are detectable in circulating cell-free DNA (cfDNA) in women with high-grade serous ovarian cancer (HGSC), according to a study published in the Journal of Clinical Oncology.1

BRCA1/2 mutations are associated with better response rates and progression-free survival with platinum-based chemotherapy and poly ADP ribose polymerase (PARP) inhibitors compared with BRCA–wild-type variants. Responses are frequently not durable, however, due to acquired resistance to therapy.

Secondary mutations that restore functionality to BRCA proteins were demonstrated to confer acquired platinum resistance in previously sensitive samples.2 The purpose of this study was to determine if such secondary mutations could be detected in cfDNA, which could affect treatment decisions for women with ovarian cancer.

Plasma and tumor samples from 30 women with primary BRCA1/2 mutations were analyzed for acquired mutations. The sample included 2 cohorts: 14 women undergoing primary HGSC debulking surgery who had had a prior cancer and 16 women with ovarian cancer recurrence.

Reversion mutations were identified in 5 patients, all of whom had disease recurrence. In 1 of these samples, cfDNA prior to chemotherapy was available and did not harbor the reversion mutation.

All patients with BRCA reversion mutations demonstrated disease resistance to platinum- or PARP-inhibitor–based chemotherapy. One patient with a reversion mutation failed therapy with cisplatin and a PARP inhibitor, but responded to gemcitabine and bevacizumab.

The sequencing results from cfDNA were matched to those of tumor DNA and indicated that a cfDNA assay specificity of 1.00, sensitivity of 0.60, positive predictive value of 1.00, and a negative predictive value of 0.90.

RELATED: Niraparib Expanded Access Program Opened for Women With Ovarian Cancer

According to the authors, these findings suggest that cfDNA can be used to detect BRCA reversion mutations and “has the potential after further evaluation to be used to direct treatment in recurrent HGSC.”

References

  1. Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, and Bowtell DD. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017 Feb 13. doi: 10.1200/JCO.2016.70.4627 [Epub ahead of print]
  2. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116-20. doi: 10.1038/nature06633

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters